Please assess the completion status of the following clinical trial:

Trial Title: Oral Vancomycin for Preventing Clostridium Difficile Recurrence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years and older~* Any history of Clostridium difficile infection based on a positive Clostridium difficile stool test performed at a lab affiliated with Rochester Regional Health System or patient report~* A new in-patient admission, with an antibiotic treatment plan for greater than 48 hours~Exclusion Criteria:~* Documented allergy and/or adverse drug reaction to vancomycin~* Pregnant~* Patients who are admitted with a current episode of Clostridium difficile infection~* Patients with total colectomy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Oral vancomycin (Type: EXPERIMENTAL): Oral vancomycin solution 125 mg in 2.5 mL, combined with 2.5 ml Ora-Sweet solution, to total 5 mL.~Taken by mouth once daily for:~1. If the total duration of systemic antibiotics is less than or equal to 14 days, oral vancomycin will be taken for the duration of the systemic antibiotics plus three days.~2. If the total duration of systemic antibiotics is greater than 14 days, oral vancomycin will be taken for the duration of the systemic antibiotics plus seven days.
- Placebo arm (Type: PLACEBO_COMPARATOR): Ora-Sweet 5 mL~Taken by mouth once daily for:~1. If the total duration of systemic antibiotics is less than or equal to 14 days, placebo will be taken for the duration of the systemic antibiotics plus three days.~2. If the total duration of systemic antibiotics is greater than 14 days, placebo will be taken for the duration of the systemic antibiotics plus seven days.

Based on this trial design, predict the completion outcome and termination type (if applicable).